Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

ASCO 2020 Science of Oncology Award Goes to Dr. Pasi A. Jänne, a Pioneer of Targeted Drugs for Lung Cancer

ASCO 2020 Science of Oncology Award Goes to Dr. Pasi A. Jänne, a Pioneer of Targeted Drugs for Lung Cancer

Founded in 1964 by 7 oncologists, the scientific organization American Society of Clinical Oncology (ASCO) holds an event in Chicago, USA, during the first week of June each year that draws the attention of cancer professionals worldwide: the ASCO Annual Meeting. With around 40 thousand attendees in recent years, it is the world’s largest oncology gathering. We wait all year for new developments in oncology to be presented at ASCO. This year, the meeting will be held online because of the COVID-19 pandemic. Another eagerly awaited announcement associated with the meeting is the ASCO awards, honoring scientists who have made major contributions to oncology. We attach particular importance to describing these awards to help explain cancer and its history. The first recipient we will discuss this year is Dr. Pasi A. Jänne.

Pasi A. Jänne (MD, PhD), a professor at Harvard Medical School, also directs the Chen-Huang Center for EGFR-Mutant Lung Cancers and the Belfer Center for Applied Cancer Science at Dana-Farber Cancer Institute. His contributions to lung cancer treatment throughout his career earned him the ASCO 2020 Science of Oncology Award. Let us look at the accomplished scientist’s interview with the American Society of Clinical Oncology’s ASCO Daily News.

"My father, Dr. Olli Jänne, was a scientist conducting extensive laboratory research. That was how I was introduced to science. Later, I decided I wanted a career combining medicine and science, and completed my MD and PhD training at the University of Pennsylvania. Combining laboratory and clinical work has always brought me great satisfaction and enabled me to become a physician-scientist. At that time, treatment success in lung cancer was low and mortality extremely high. Perhaps that was why wanting to work in lung cancer was considered a somewhat unusual choice. However, I saw it as a good opportunity and felt the need to find a new approach, so I decided to pursue this field."

Dr. Jänne’s determination became evident in a discovery he made about lung cancer in 2004.

The Scientist Who Changed the Course of Lung Cancer

The limited response of a type of lung cancer, non-small-cell lung cancer, to chemotherapy was the starting point for Dr. Jänne’s research. Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein with an extracellular binding site for growth factor and an intracellular tyrosine kinase domain that controls cell proliferation (see the infographic below). When this receptor binds to growth factor, it activates intracellular signaling pathways and triggers cell division. However, persistent stimulation of these pathways leads to aggressive tumors, and somatic mutations or chromosomal alterations in the protein kinases involved in these pathways are among the most common mechanisms of tumor formation.

It was at this point, in 2004, that Dr. Jänne discovered a relationship between EGFR mutations and response to EGFR kinase inhibitors used to treat patients with non-small-cell lung cancer. He describes the work his team conducted in cell lines and lung cancer patients as follows: "Clearly, some patients respond better to treatment. Median survival after inhibitor treatment is 3.1 years in EGFR-mutation-positive patients, compared with 1.6 years in EGFR-mutation-negative patients. Our studies have demonstrated that this is no coincidence: changes caused by somatic mutations make EGFR more sensitive to inhibitors." Shortly after the discovery, EGFR mutation testing began to be incorporated into standard treatment protocols for newly diagnosed lung cancer patients at medical centers internationally. As a result, 5 new EGFR inhibitors—erlotinib, afatinib, gefitinib, dacomitinib, and osimertinib—were developed and approved for advanced EFGR-mutant non-small-cell lung cancer. Dr. Jänne notes that these widely used targeted cancer drugs, directed at genetic targets such as EGFR mutations, take priority over chemotherapy in advanced EGFR-mutant lung cancer. He says he is honored to have been part of this success.

Continuing his lung cancer research, Dr. Jänne summarizes his current work: "With treatments using EGFR inhibitors, we still see drug resistance (studies show that other mutations cause this resistance). We ask ourselves how we can combine these drugs, developed as individual EGFR inhibitors, to improve treatment response. How can we manage these combinations, especially in people with other chronic conditions? To answer these questions, our laboratory conducted preclinical studies of combinations involving three different drugs—gefitinib-osimertinib and osimertinib-selumetinib—and obtained promising results. This allows us to move into clinical trials. The coming days will show whether we achieve our goal. We must also remember that this field still faces many challenges, and aspects of lung cancer biology remain incompletely understood. We must therefore continue trying to understand the biology of diseases. We know very well that understanding the biology better will lead to much more successful outcomes."

Dr. Pasi A. Janne and colleagues

Emphasizing that his research is a team effort, Dr. Jänne thanks his collaborators Nathanael Gray (PhD, on the left in the photograph), Michael Eck (MD, PhD, on the right) and Kwok-Kin Wong (MD, PhD). The paths he has opened in cancer research give us great hope.

Sources

1. Dr. Pasi A. Jänne Honored With the Science of Oncology Award. https://dailynews.ascopubs.org - 13 May 2020.

2. Bethune, G., Bethune, D., Ridgway, N., & Xu, Z. (2010). Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. Journal of thoracic disease, 2(1), 48–51.

3. Le, T., & Gerber, D. E. (2019). Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?. Cancers, 11(3), 366.

4. Paez JG, Jänne PA, Lee JC, et al. EGFR Mutations in Lung Cancer: Correlation With Clinical Response to Gefitinib Therapy. Science. 2004;304(5676):1497-500.

5. Tetsu, O., Hangauer, M. J., Phuchareon, J., Eisele, D. W., & McCormick, F. (2016). Drug Resistance to EGFR Inhibitors in Lung Cancer. Chemotherapy, 61(5), 223–235.

6. Sequist LV, Joshi VA, Jänne PA, et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 2007;12:90-8.

7. Da Cunha Santos, G., Shepherd, F. A., & Tsao, M. S. (2011). EGFR Mutations and Lung Cancer. Annual Review of Pathology: Mechanisms of Disease, 6(1), 49–69.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

ASCO 2020 Science of Oncology Award Goes to Dr. Pasi A. Jänne, a Pioneer of Targeted Drugs for Lung Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy